www.fdanews.com/articles/177611-loxo-oncology-secures-breakthrough-designation
Loxo Oncology Secures Breakthrough Designation
July 20, 2016
Loxo Oncology has scooped up a breakthrough therapy designation for its tropomyosin receptor kinase inhibitor candidate LOXO-101, the Stamford, Conn.-based company announced.
The drug candidate is designed to treat unresectable or metastatic solid tumors that have NTRK-fusion proteins in adult and pediatric patients with disease progression after treatment or those who don’t have other appropriate options.